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Abstract
Objectives The aim of this study was to investigate
experiences with and attitudes toward generic substitution
in patients on antihypertensive medication.
Materials and methods Study participants were 22 patients
from pharmacies in Oslo who had taken brand antihyper-
tensive products as well as substituted generic products.
Five focus- group discussions were held.
Results Only a few participants claimed to take their
medications as prescribed. Most reported low drug adher-
ence before and after generic substitution. Fourteen said
that their blood pressure was not under control. Most
patients did not know what it meant to get a generic
product. They normally accepted what the pharmacy
offered, even if they thought the generics were of a lower
quality than the brand products. Five participants experi-
enced new side effects. Differences in name, color, form, or
taste caused confusion. The patients had been told in the
pharmacy that the effect of a generic product was as good
as that of the brand product but were still confused, as in
most cases the doctor said nothing to them about the
substitution.
Conclusion Generic substitution works well in Norway as
an economic health strategy, but drug adherence remains
suboptimal under those circumstances. Patients are insecure
with respect to the difference between the old and the new
product when it comes to the drug’s physical attributes and
perceived quality. Patients would feel safer if the doctor had
a more active role in informing them about the system.
Keywords Generic substitution.Hypertension.Drug
adherence.Drug information.Focus-group discussions
Introduction
In the Nordic countries, generic substitution was introduced
in 1995 in Denmark [1], followed by Norway in 2001 [2],
Sweden in 2002 [3], and Finland in 2003 [4]. This was a
less radical measure than would be the introduction of
generic prescribing–the main form for prescribing in Great
Britain and a few other European countries [5]. Generic
substitution is an economic health strategy to diminish the
government’s refunding costs of prescription drugs [2, 3, 6].
Itisessentialforpatientsaswellasforhealthcarepersonnelto
be aware that when compared with the brand product, the
generic alternative contains the same amount of the same
active compound and is of the same quality and safety [7].
However, the patient on the receiving end is getting a
product with a different brand name and possibly in a
different form, size, color, or taste. Consequently, challenges
arise when it comes to taking the drug appropriately, and the
patient may become confused [7].It is also important to be
aware that it has been known for many years that drug
adherence without generic substitution is on average only
50% for patients taking chronic medication [8].
Generic prescribing is authorized in Norway, but the
system is not being practised in more than about 2% of
prescriptions [9]. The use of generic substitution has,
however, risen dramatically and almost reached 40% of the
market share in defined daily doses (DDD) in 2008/2009 [7].
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DOI 10.1007/s00228-010-0935-xGeneric substitution was introduced in Norway at the
same time as a new pharmacy act. This implied that, for the
first time, international chains could own pharmacies. The
different chains are licensed to have different products in
stock. In other words, patients who use more than one
pharmacy may be getting different generic products. The
pharmacist is obliged to suggest substituting the prescribed
pharmaceutical product for the cheapest interchangeable
generic unless the physician has marked on the prescription
that substitution should not take place. The patient can,
however, insist on the brand product but will then have to
pay an additional fee. As the government in Norway
refunds most prescription drugs, the concept of additional
fees was relatively new to the patients, even though other
similar strategies have been tried out for about a 10-year
period. [2]. However, no marked difference between social
classes has been shown when it comes to the use of generic
drugs, unlike in many other countries [10].
Using a structured questionnaire, our group previously
interviewed 174 patients who took both brand and generic
antihypertensive products [7]. We found that as many as
one in three said that generic substitution made it more
demanding for them to cope with their medication. Three
out of ten said they were anxious when they started to use a
generic product [7]. We also found that 8% of the patients
said they noticed a poorer effect of the new drug, and 15%
experienced new side effects [7]. In Sweden, it was found
that increased generic market shares increased the number
of reported side effects for seven of 15 active ingredients
[11]. In Denmark, 6% in a study of 86 patients experienced
more side effects [12]. In another Norwegian study, one in
three patients reported new side effects or a change in the
effect of the drug after generic substitution [13]. In a US
study, between 14% and 54% of 500 patients, depending on
their medical condition, claimed that generic drugs were
less safe than the brand products [14].
The aim of this study was to investigate the views on
and attitudes toward generic substitution in patients on
antihypertensive therapy when they were allowed to talk
freely in focus groups about their own experiences. How
did the substitution affect their drug adherence, and how
knowledgeable were they, in fact, about the situation?
Patients and methods
Patients
The study group consisted of 22 patients (15 men, seven
women) using five pharmacies in Oslo. Patient age range
was 51–76 years. All informants had experience with
antihypertensive drugs both as brand products and then as
substituted generic products.
Method
Fivepharmacieswheregenericsubstitutionoccurredtoahigh
degree and thatweregeographicallyspread out acrossthe city
were selected based on information provided by the three
large pharmacy chains that exist in Norway. An information
meeting about the study was held with the personnel in each
pharmacy. Patients between 50 and 80 years of age were
asked to take part in the study if they had been taking brand
antihypertensive drugs and later changed at least once to a
generic product. Patient recruitment was conducted from
April to September 2004. The pharmacies received 30
invitation letters each to give to patients who fulfilled the
criteria for participation. The patients were also informed in
person. Those who agreed to participate had to send their
written reply in a prestamped envelope. Focus-group inter-
views were used as the research method. Five groups of five
patients each were formed randomly according to when the
returnedenvelopeswerereceived.Threepersonsneverturned
up.Asimplequestionnairewashandedoutatthebeginningof
each session to obtain some background information about
the patients. An interview guide that included the main areas
to be discussed was used. The areas were: participants’
perception of their drug adherence; participants’ knowledge
about generic substitution; possible effect of generic substi-
tution on their drug adherence; possible effect of the
physician’s attitude toward generic substitution in relation to
their adherence; and possible effect of the pharmacist’s
behavior in relation to their adherence.
The first focus-group discussion was the pilot study. As
nothing needed to be changed in the interview guide after
that first study, the study was included in the results as one of
the five focus-group discussions. The same researcher did all
the focus-group interviews. A note-taker was present at all
interviews and was consulted by the facilitator before data
analysis. Each focus group lasted between 1.5 and 2 h. The
patients gave their informed consent in writing. The study
was approved by the Norwegian Regional Ethics’ Committee
and the Norwegian Social Science Data Services. The group
interviews were recorded, transcribed, and analyzed by the
data program QSR Nudist N4 Classic. This method sorts data
according to relevant categories and topics to get a better
overviewoftheinformationcollected.Thecategorieswerethe
same as the areas mentioned above as main areas of the
interview guide.
Results
Patient background information
Nineteen of the 22 participants were diagnosed with
hypertension, whereas three suffered from various cardiac/
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antihypertensive medicines for >10 years. Table 1 shows
more detailed information about participants’ drug use. No
patient used drugs extensively.
Patients’ perception of their own drug adherence
Only a few patients reported that they took their medication
as prescribed, and as many as half of them said that they
omitted taking a dose quite often. Especially the evening, the
dose was easy to forget, and if they were busy or on holiday,
not all doses were usually taken. Several informants claimed
to be sceptical about using drugs in general and never felt at
ease about taking any kind of medication. However, they
explained that they had made a decision to take their
antihypertensive medication. One informant was explicit
about not being alive without it. In some groups, patients
were afraid of becoming addicted to the drugs and were
convinced that that can happen very easily with any form for
drug. They felt that it would be an especially unfortunate
outcome if they were to become addicted to antihypertensive
drugs, as they were of the opinion that these drugs have
many adverse reactions. The participants in all five groups
were, in fact, very preoccupied with adverse drug reactions,
and their opinion was that, apart from forgetfulness, fear of
such reactions was the most usual reason for nonadherence.
In one group, participants talked about the well-being
they felt when being adherent. One person said:
“I believe that it has a certain psychological effect. As
long as I take my medicine every day, and at the same
time every day, I know that I am on the safe side.
What might happen afterwards is not my fault. I have
done what I could.”
On the other hand some patients expressed the feeling that
it did not matter if they forgot to take the tablets, as
hypertension in their opinion was not a serious condition.
For example, one person said:
“I forget because I look at myself as a healthy person,
something I have always been.”
A few said that “their body told them” if they had not taken
the tablets, whereas others meant that it was better to rely
on a “dosette” box. Fourteen patients claimed that their
blood pressure was still too high. Eight said, however, that
they had a normal blood pressure. Those eight were
convinced that it was because of their medication.
Patients’ knowledge about generic substitution
When the patients were asked directly what it meant to get
a generic product, most answered that they did not know.
Some were also of the opinion that the pharmacists were
educated enough to know what to give them and that they
therefore had no need to bother. One informant had this
answer:
“It is when they give you something else in the
pharmacy without having to phone to the doctor to
ask for permission.”
There were a few, however, who said they knew that the
active ingredient had to be the same whereas the excipients
could be different. Many participants said that they often
asked for the brand medicine when they were given
generics in the pharmacy—to feel safe:
“After all you prefer to have what the doctor has
prescribed.”
They normally accepted what the pharmacy offered. By the
time of the interview, 19 of 22 patients used generic
products. Three had changed back to the brand product.
One participant said she hoped they told her the truth in the
pharmacy when they said that she got a drug that was as
good as the brand product, even if it was cheaper. Others
claimed that if the doctor and the pharmacist had said the
same thing, they would not have thought so much about it
when the drug was changed in the pharmacy. One said:
“The doctors prescribe what they find when they look
in their book, and the pharmacists sell you what they
find in their shelves, isn’ti t ”?
In what way does generic substitution influence adherence?
There was a big variation in time since the different
participants started generically substituted products. Some
had used them since the system started, whereas a few had
used them only for some weeks. Most patients had had the
product changed once or twice since they got the
prescription with the brand name. One person had received
four different generic products on four different occasions.
All participants indicated that they heard that the new
product was meant to have the same effect as the brand
drug. Some were explicit about the fact that they under-
stood the situation and explained that they first used the
tablets they had at home, which had a different name, and
Table 1 Daily drug use of the 22 patients in the study
No. of patients
One antihypertensive drug 11
Two antihypertensive drugs 11
Regular, additional use of prescribed medicines 10
Regular use of over-the-counter medicines 5
Taking more than seven tablets per day 3
Eur J Clin Pharmacol (2011) 67:33–38 35then started with the new ones. However, at the same time,
even if they took their generic products, almost every
participant was of the opinion that the generic product was
of a lower quality than the brand product. One lady
expressed it like this:
“It is probably good enough for me. It is like when
you buy a pullover which is not so expensive. It can
still be warm enough. Or you can buy a Rolex watch
in Singapore. It still works”.
When they talked about how differences between the
products could be a reason for nonadherence, they mainly
talked about the physical differences, such as form, color,
and size. One person said:
“It is confusing now when I get square tablets. I used
to take round ones”.
A few had problems with the new tablets being too big for
their dosette. This messed up their adherence as a result.
One ended up not knowing what she took after she had
forced the tablets into the dosette box:
“When I press the lid on now, some of the tablets
break, and then I don’t know what I take”.
A few felt that their adherence had deteriorated after they
changed to a blister pack, as it was irritating to have to press
the tablets out. Others missed the blister pack they had before,
where they could see if the tablet had been taken or not.
The participants were also discussing whether changes in
effect/side effects might have changed their adherence. Five
reported that they experienced new side effects when
starting with generics and had therefore at first been a bit
apprehensive about taking the new medication. Three
wondered, however, if the dizziness and/or sickness was
“psychological,” as they had expected something “bad” to
happen. One person was sure that the new side effect she
felt came from a new excipient, as she said she knew that
the active ingredient was the same. All in all, there was a
general agreement that to switch to a generic product had
not changed their drug adherence markedly. However, they
more or less agreed that it was “as bad as before”. There did
not seem to be any gender or age differences regarding how
they took their tablets.
Effect the physician’s attitude may have on the patient’s
adherence after generic substitution
Most participants expressed a great trust in their doctor. In
particular, women in the study spent considerable time
discussing that topic.
“You believe in your doctor, so when you come to the
pharmacy and they give you something else than what
the doctor has prescribed, you feel insecure. You sit at
home and think that the new tablets don’t work as the
old ones, because if it is the same thing, why did not
the doctor prescribe it?”
Another expressed the trust like this:
“I don’t think it is all right to use medicines, but I feel
that if I don’t take what the doctor says, something
bad can happen”.
However, in general, the informants had the impression that
doctors could be more updated and that the situation would
be easier if the doctor told them they might get another
product than the prescribed one. Some also thought it a
good idea if the doctors more often prescribed generic
products. One half of the patients said they had not thought
about telling their doctor that the drug was changed by the
pharmacy or that they had not told the doctor because they
felt uncomfortable doing so. The other half had told their
doctors, and most doctors had answered that the effect on
blood pressure was the same. However, only a few doctors
prescribed the generic product the next time. There were
also doctors who had been negative, and one informant
said:
“I said to my doctor that I don’t get the medicines he
prescribes. He answered that he thought the changing
system is a lot of nonsense”.
Effect of the pharmacist’s behavior on the patient’s adherence
Participants were asked to tell where they got their
information on generic substitution. Every person claimed
that it came from the pharmacy, and many added that they
had never heard about the system before they were offered
such products. Some had read about it in the newspaper
afterwards. They all indicated that the pharmacy personnel
said that the generic product was as good as the brand
product and that it was cheaper. One added:
“I have changed into several new products. Every
time they ask if it is OK that I change, and every time
the new one turns out to be cheaper. So you see, it is
only about economy”.
Several patients said they trusted the pharmacy, whereas
others said they felt that they just had to trust them:
“When they say it is the same ingredient, I have to
trust them, I have no other choice. You cannot say to
them: sorry, you are mistaken (laughing)”.
It was a general opinion that the pharmacies were too active
in having them change products. Some felt it very
unpleasant to have to negotiate when they wanted the
36 Eur J Clin Pharmacol (2011) 67:33–38prescribed drug. In fact, many were of the opinion that the
pharmacies produced their own cheap products and
therefore wanted so much to sell them.
Discussion
Patients in this study were all taking brand hypertensive
products before they had their medication substituted at
least once into generics. Other studies have already shown
that generic substitution often confuses people [7, 11–14].
One study was done by our group [7] where we showed, by
a quantitative method, that patients felt anxious and
insecure about generic substitution. That caused an additional
challenge for drug adherence. Adherence after generic
substitution has also been studied using prescription data
bases. In such a scenario, it is only possible to look at results
on a group level without knowing what is really taken by the
individual [15]. Such results are even more difficult to use in
a country such as Norway, in which the state pays as much
as 70% of total drug expenditures.
The aim of using focus groups was to determine in more
detail how the individual patient experiences the situation
with generic substitution. A focus group interview is a
qualitative research method that can be especially useful
when the topic is sensitive. Patients are, in general,
admitting more when they get together and hear each
others’ stories [16]. This is shown in the results of the study
reported here, when the antihypertensive patients talked
about how their drug adherence has never been good and in
fact only eight of them claimed that their blood pressure is
under control. A few also added that their drug adherence
deteriorated after generic substitution. Whereas 17% of
participants in the quantitative study said they quite often
did not take their medication as prescribed, in this study, 90%
said the same thing. This finding illustrates what can be
revealed when using focus groups. It can be argued that there
is a limitation per se to involve few participants. However, we
consider using different methods to find as much information
about a topic as possible extremely useful. It is also an
important factorthatwehad participantsfromthe samecityin
the two studies.
Participants were uncertain about how the system with
generic substitution really worked. As most of them repeat-
edly received new generic drugs in the pharmacy, and as the
tablets often changedinsize,color,ortaste,theywereoften of
the opinion that the pharmacist gave them what was on hand,
and it was a general opinion that they got drugs of lower
quality. When compared with the quantitative study in which
15% of participants claimed to have experienced new side
effects [7], 23% claimed the same in this study. This is
probably not a bigger difference than may be found between
anytwo differentstudies;if anything, the patientsinthisstudy
admittedmorebecausetheywereparticipatinginfocusgroups.
In Norway, as much as 10% of the population is using
antihypertensive drugs [17]. As generics have risen to 40%
of the market shares, many hypertensive patients are offered/
using generic drugs. It is therefore a big challenge for
healthcare personnel to help the patients understand the
system so they do not end up with an even poorer drug
adherence than before. In the quantitative study, for instance,
itwasfoundthatonein20patientstooktheoriginalproductas
well as the generic [7].
Patients in our study had a great trust in their doctor.
However, in general, they felt they did not get information
from him/her about being given a different product
(generic) than the prescribed (brand name) one when they
went to the pharmacy. Half the patients had told the doctor
afterwards about the substitution, but many doctors did not
support it. Also, when we studied generic substitution in
one of Norway’s biggest hospitals, we found that doctors
took little part in supporting the system [18]. As the
participants in this study were allowed to talk freely in the
focus groups, it was quite clear that they felt the pharmacy
personnel were pressing them too hard to accept generic
products. It was also because of the open discussion that
participants expressed they often thought that either the
doctor or the pharmacist had to be wrong. This study
therefore shows better than other studies how important it is
that doctors play a more active role in providing informa-
tion about generic substitution.
Conclusion
Generic substitution works well in Norway as an economic
healthstrategy.However,drugadherenceremainssuboptimal
under those circumstances. Patients are insecure about the
situation with respect to the difference between the old and
the new product when it comes to the drug’s physical
attributes and perceived quality. New side effects and a
poorereffectwerereported.The generalopinionofpatientsis
that they would feel safer if the doctor had a more active role
in informing them about the system.
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